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Abstract
Idiopathic pulmonary fibrosis is characterized by a progressive scarring and stiffening of the peripheral lung tissue that 
decreases lung function. Over the course of the disease, the lung microvasculature undergoes extensive remodeling. There 
is increased angiogenesis around fibrotic foci and an absence of microvessels within the foci. To elucidate how the anti-
fibrotic drug nintedanib acts on vascular remodeling, we used an in vitro model of perfusable microvessels made with 
primary endothelial cells and primary lung fibroblasts in a microfluidic chip. The microvasculature model allowed us to 
study the impact of nintedanib on permeability, vascularized area, and cell–cell interactions. The anti-vasculogenic impact 
of nintedanib was visible at the minimal concentrations of 10 nM, showing a significant increase in vessel permeability. 
Furthermore, nintedanib decreased microvessel density, diameter, and influenced fibroblast organization around endothelial 
microvessels. These results show that nintedanib acts on the endothelial network formation and endothelial–perivascular 
interactions. Advanced in vitro microvasculature models may thus serve to pinpoint the mechanistic effect of anti-fibrotic 
drugs on the microvascular remodeling in 3D and refine findings from animal studies.
Keywords Microvasculature-on-a chip · Nintedanib · Neovasculogenesis · Vascular permeability · Idiopathic pulmonary 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and pro-
gressive pulmonary disorder, where progressive scarring of 
the peripheral lung ultimately leads to loss of lung func-
tion. IPF has a poor survival prognosis, a median survival of 
2–3 years after diagnosis [1]. Some patients progress slowly, 
while others have episodes of acute exacerbations which 
lead to a quick decline in lung function [2]. The underlying 
cause of IPF is still unknown, but several risk factors have 
been identified. Smoking, exposure to pollutants, genetic 
predisposition, viral infection, gastro-esophageal reflux and 
aging increase the risk of developing IPF [1].
Typically, IPF patients have regions of stiff fibrotic tissue, 
which look like honeycombs on the macroscale. In these 
regions, extracellular matrix secreted by myofibroblasts 
accumulates, and there are dilated spaces, disruption of the 
alveolar barrier and epithelial hyperplasia [3]. IPF not only 
alters the normal lung parenchyma by progressive fibroblast 
proliferation and extensive deposition of extracellular matrix 
(ECM), but also non-homogenously remodels the pulmonary 
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microvascular and macrovascular architecture [4]. Density 
of blood vessels in fibrotic regions is less, while adjacent 
non-fibrotic tissue is highly vascularized [5]. It is unclear 
whether neovascularization is a compensatory mechanism 
or whether it rather promotes disease progression.
Studies on IPF therapeutic compounds have largely 
focused on fibrosis and the knowledge is limited regarding 
IPF-associated vascular remodeling. However, recent find-
ings suggest that the underlying pathobiology in IPF is much 
more intricate, and associates with a complex interaction 
between epithelial cells, fibroblasts, and endothelial cells 
[5]. These complex interactions are regulated by variety of 
angiogenesis promoters, inhibitors, and growth factors [5].
More light is starting to be shed on IPF pathogenesis with 
the introduction of tyrosine kinase inhibitors used to treat 
IPF. Nintedanib is a potent small molecule that inhibits the 
angiogenic receptor tyrosine kinases of fibroblast growth 
factor receptor (FGFR), vascular endothelial growth factor 
receptor (VEGFR), and platelet driven growth factor recep-
tor (PDGFR) [6]. The in vitro efficacy of nintedanib was 
explored in vascular endothelial growth factor (VEGF)- or 
fibroblast growth factor (FGF)-2-stimulated human umbili-
cal vascular endothelial cells (HUVECs), pericytes stimu-
lated with platelet driven growth factor (PDGF) and FGF-2, 
and TGF-β-induced primary culture of lung fibroblasts from 
IPF patients [7]. Nintedanib induced apoptosis in HUVECs 
and pericytes in a concentration-dependent manner, and 
reduced collagen secretion and deposition by IPF fibroblasts 
[6]. The anti-fibrotic, anti-inflammatory, and anti-angiogenic 
effects of nintedanib were demonstrated in models of sil-
ica-induced lung fibrosis in mice and bleomycin-induced 
lung fibrosis in mice and rats [8, 9]. Recently, a bleomycin 
induced mouse model of lung fibrosis provided evidence 
that the anti-angiogenic activity of nintedanib recovered 
pulmonary microvasculature architecture and improved 
lung function in pulmonary fibrosis [10]. However, addi-
tional studies are needed to elucidate the mechanism of 
angiogenesis and vasculogenesis inhibition after treatment 
with nintedanib [10]. Differences in the cellular responses 
observed in standard in vitro studies, animal models, and 
human clinical studies may be confounding and hinder the 
efficient development of new therapeutic strategies. This is 
especially true for disease such as IPF which is known for 
complex correlation of fibrosis, angiogenesis and growth 
factor signaling [11]. Advanced in vitro microvasculature 
models that mimic in vivo conditions of human lung are one 
strategy to better understand the pulmonary vascular remod-
eling and investigate the efficacy of therapeutic compounds.
Recently, thanks to the development of advanced 3D 
in vitro models, the feasibility of self-assembled perfus-
able microvessel networks has been established [12–16]. 
Such models have several important features of the vas-
cular microenvironment in vivo, and enable fine spatial 
and temporal resolution during in vitro experiments [14]. 
Based on an in  vitro vasculogenesis model using co-
culture of endothelial cells and pericytes, Bichsel et al. 
[12] described the biomimetic model of lung parenchyma 
microvasculature. This microfluidic co-culture system ena-
bled the formation of a microvessel network that resem-
bles human lung microvasculature in terms of morphology, 
vascular marker expression, permeability, and vasoactive 
response [12]. In another study, vessel formation by angio-
genesis and vasculogenesis was achieved by co-culture of 
endothelial cells and human lung fibroblasts [13]. This 
vascular network displayed integral barrier function and 
long-term vascular stability [13]. These in vitro microflu-
idic models mimic the in vivo microenvironment much 
better than conventional in vitro assays. Co-culture of 
endothelial cells and fibroblasts or pericytes self-assemble 
their stable and perfusable microvasculatures within the 
three-dimensional microenvironment. Although in vitro 
tissue models do not completely mimic the complexity 
of in vivo conditions [17], these models might provide 
a unique system to investigate the efficacy, toxicity, and 
mode of action of therapeutic agents, such as nintedanib.
The objective of this study was to investigate how the 
anti-fibrotic drug nintedanib acts on vascular remodeling 
on an isolated 3D microvasculature network. Firstly, we 
established a 3D, stable and perfusable microvasculature 
network by co-culturing primary human lung fibroblasts 
and primary human umbilical vascular endothelial cells 
(HUVECs) within 3D fibrin gel network. Secondly, we 
explored the impact of nintedanib in this in vitro model of 
microvasculature architecture by investigating changes in 
vascular permeability, vessel density, fibroblast invasion, 
and endothelial-fibroblast interactions.
Materials and methods
Chip fabrication
The microfluidic device and fabrication process have been 
previously described in detail [12]. The chip used in our 
study is 100 µm in height, with five compartments, three 
chambers, and two microchannels separated by trapezoidal 
micropillars. The micropillars were spaced 100 µm apart, 
the diameter of the central circular chamber was 2 mm, 
and the adjacent microchannels and outermost chambers 
are 1 and 0.5 mm wide, respectively. To prepare the chip, 
a mixture of polydimethylsiloxane (PDMS; Sylgard) and 
curing agent was cast on a master mold fabricated by pho-
tolithography. After cutting and punching the access reser-
voirs, the PDMS pieces were treated with oxygen plasma 
and bonded to coverslips.
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Cell culture
Primary HUVECs (PCS-100-010; ATCC, USA) were cul-
tured with endothelial growth medium 2 (EGM2; Lonza). 
Normal human lung fibroblasts (NL-FBs) were acquired 
from healthy lung tissue from patients undergoing tumor 
resection at the University Hospital, Bern, Switzerland, and 
cultured as mural cells with Ham’s F-12K (Kaighn’s) cell 
culture medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin–streptomycin. Details of the NL-
FBs are available elsewhere [18]. Patients gave informed 
consent and primary cell culture was approved by the local 
ethical committee. For all experiments, HUVECs and NL-
FBs were used between passage four and nine.
Cell seeding and chip maintenance
Microfluidic chips were sterilized in an ozone chamber 
(CoolCLAVE) before seeding cells. HUVECs and NL-FBs 
were suspended in 2 U/ml bovine plasma thrombin (Sigma) 
in endothelial basal medium 2 (EBM2; Lonza) at final con-
centrations of 2 × 107 and 1 × 107 cells/ml, respectively. 
A solution of 10 mg/ml fibrinogen from bovine plasma 
(Sigma) in PBS (Gibco) was prepared. For co-culturing, 
HUVECs, NL-FBs, and fibrinogen solution were mixed 
at a ratio of 1:1:2 and immediately seeded into the central 
chamber. Next, a 1:1 mixture of NL-FBs and fibrinogen 
solution was immediately loaded in the outermost cham-
bers. After 10 min, EGM2 was loaded in the microchannels 
and the reservoirs were filled. All chips were incubated at 
37 °C with 5%  CO2. Further details of chip co-seeding are 
available elsewhere [12]. A solution of 10 mM nintedanib 
(BIBF 1120) was prepared in 1 ml DMSO (S1010; Sell-
eck Chemicals) and diluted for experimental use in EGM2. 
Treatment with nintedanib started on day 1, and both treated 
and untreated samples were cultured for 7 days. Medium 
(with or without nintedanib) was exchanged every 24 h. Dur-
ing medium exchange, a transient pressure difference was 
created to ensure flow of the new medium to cells in the 
central circular chamber.
Immunostaining
The immunofluorescence staining protocol has been 
described previously [12]. Briefly, samples were incubated 
overnight with a primary antibody to the endothelial marker 
PECAM-1 (Santa Cruz) diluted 1:200 in 2% BSA in PBS. 
Samples were incubated with secondary antibodies conju-
gated with 488 Alexa Fluor (Molecular Probes), phalloidin 
(1:100; Invitrogen), and Hoechst (1:1000; Invitrogen) for 
2 h at room temperature. All images were collected using 
a Zeiss LSM 710 confocal laser scanning microscope (Carl 
Zeiss Microscopy, LLC, Thornwood, NY).
Live cell imaging
To observe the effect of nintedanib on endothelial-fibro-
blast interaction and fibroblast invasion, cell membrane 
labeling was carried out with the lipophilic cell tracker 
dyes PKH67 for HUVECs (green) and PKH26 for NL-FBs 
(red) before chip loading. Two different strategies were 
used for cell seeding and treatment. In all chips, NL-FBs 
in fibrin gel were seeded into the two outermost chambers, 
but some chips contained a mixture of HUVECs and NL-
FBs in fibrin gel in the central chamber, whereas others 
had only HUVECs in fibrin gel. To study the effect of nin-
tedanib on vasculogenesis, chips were treated with 50 nM 
nintedanib in EGM2 for 7 days. To evaluate the effect of 
nintedanib on angiogenesis, chips were treated with 50 nM 
nintedanib only on days 4–7, after formation of the prema-
ture microvasculature network. The chips were placed in 
an Omnitray, transferred to the Nikon BioStation CT, and 
imaged every 2 h. Chips remained inside the machine for 
7 days, and medium was exchanged every 24 h.
Vascularized area and diameter quantifications
In the central chamber, PECAM-1-positive regions were 
defined as vascularized areas. Z-stacks obtained from con-
focal microscopy were projected on a plane with maximum 
signal intensity using Fiji image analysis software [19]. 
Using the DiameterJ Segment plugin in Fiji [20], projected 
images were segmented using eight different thresholding 
techniques, and the most resembling segmentation to the 
original image was analyzed. The segmented image was 
analyzed using the DiameterJ 1-018 plugin [20] to quan-
tify diameter distribution, number of intersections, and 
minimal and maximal diameters. Vascularized area frac-
tion was defined as the area covered by vessels divided by 
the whole area of the central chamber and measured using 
the “Measure” option in Fiji.
Microvessel permeability measurement
To assess the impact of nintedanib on microvessel 
wall integrity, vascular permeability was calculated as 
described previously [21]. Briefly, at the end of day 7, 
medium was removed from all reservoirs and 70 kDa rho-
damine isothiocyanate (RITC)-conjugated dextran (Sigma) 
was added to one of the reservoirs at a concentration of 
1  mg/ml in PBS. Starting immediately before RITC-
dextran loading, images were acquired every 10 s using a 
Leica DMI 4000 microscope. The microvascular perme-
ability coefficient was calculated based on the intensity 
of the fluorescence dye across the vascular wall over time 
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using Fiji software. Five different regions per chip were 
quantified.
Colocalization measurement
Colocalized area, defined as areas of overlapping HUVECs 
and NL-FBs in the central chamber, was calculated to quan-
tify the effect of nintedanib on fibroblast localization around 
endothelial vessels. Images from the red (NL-FB) and green 
(HUVEC) channels were obtained from the Nikon BioSta-
tion CT on day 7, merged, and quantified using the Coloc 
plugin in Fiji [19] for colocalization analysis via intensity 
measurement. An image of overlapping areas was produced 
and then analyzed to obtain the area fraction measurement. 
At least five different areas per chip were quantified to cal-
culate this percentage.
Cellular health assessment
The proliferation rate of mono- and co-cultured HUVECs 
and NL-FBs was determined using the Cell Viability Imag-
ing Kit (Blue/Green; ReadyProbes) according to the manu-
facturer’s protocol. Cells were resuspended in EGM2 and 
seeded into 96-well plates at densities of 2500 cells per well 
(HUVECs), 600 cells per well (NL-FBs), or 1600 cells per 
well (co-culture of HUVECs and NL-FBs). Nintedanib was 
diluted in EGM2 and added to cells at final concentrations of 
10, 50, and 100 nM. Plates were seeded in duplicate to per-
form the assay twice, on days 4 and 7. A cocktail consisting 
of two drops each of stable NucBlue® Live (Hoechst 33342) 
and NucGreen® Dead reagents in 1 ml media was prepared, 
and 80 µl was added to each well. Samples were incubated 
for 15 min at room temperature then imaged using a Leica 
DMI 4000 microscope. At least two regions of each well 
were imaged. After binarizing the image and using “Particle 
Analysis” in Fiji, the numbers of live and dead cells were 
obtained. In addition to the proliferation assessment, the 
alamarBlue assay was used to evaluate cellular health after 
treatment with nintedanib. A 96-well plate was prepared as 
described above and treated with various concentrations of 
nintedanib. On day 7, the alamarBlue assay was performed 
according to the manufacturer’s protocol. After 2 h of incu-
bation with alamarBlue, the absorbance was measured using 
a plate reader (TECAN). Absorbance values were corrected 
for background absorbance. Viability percentages reflect 
the ratio of the each absorbance value to average of control 
(0 nM) for each cell-culturing condition.
Statistics
All data represent mean ± standard deviation of number of 
cases. Statistical variations between groups were analyzed 
using an unpaired t test, and p values less than 0.05 were 
considered statistically significant. Statistical analysis was 
performed using GraphPad Prism 6 software.
Results
Establishment of in vitro perfusable 
microvasculature network
Flow channels were connected to the central chamber and 
side chambers via openings between trapezoidal pillars to 
supply nutrients and growth factors to cells located in these 
compartments (Fig. 1a, b). After 7 days of co-culturing 
HUVECs and NL-FBs (cell density ratio, 2:1), three-dimen-
sional perfusable microvessels had formed in the central 
chamber. Immunostaining for PECAM-1 showed the exist-
ence of adherent junctions between endothelial cells that 
formed a microvasculature network (Fig. 1c, d).
Interconnectivity and perfusability are two key features 
of a functional vasculature model. To demonstrate the inter-
connectivity and perfusability of the vasculature network in 
our system, 70 kDa RITC-dextran was loaded in one of the 
reservoirs (Supplementary Material Video S1). Fluorescent 
dye flowed into the microvasculature network through the 
openings between the trapezoidal pillars. The calculated per-
meability coefficient was (1.5 ± 0.32) × 10−6 cm/s, which is 
similar to values measured for mammalian venules and other 
in vitro vasculature models [12, 22].
Effect of nintedanib on cell proliferation 
and viability
We performed live/dead staining of cells after 4 and 7 days 
of treatment with nintedanib. Nintedanib did not have an 
anti-proliferative effect on HUVECs, NL-FBs, or their co-
culture in concentrations up to 100 nM (Fig. 2a). To assess 
the cytotoxicity of nintedanib, we utilized alamarBlue, a col-
orimetric assay in which absorbance is related to the num-
ber of living cells and depends on metabolic activity [23]. 
Nintedanib did not show cytotoxic effects and cells main-
tained viability after 7 days of treatment with nintedanib at 
concentrations up to 100 nM (Fig. 2b). The proliferation 
and viability of monocultures and co-cultures showed that 
100 nM nintedanib was not cytotoxic in that context.
Nintedanib increases microvascular permeability
The particular design of our microfluidic chip enabled self-
assembly of a perfusable microvasculature network in the 
central chamber, allowing us to investigate the action of 
nintedanib on microvascular barrier integrity and perme-
ability. Untreated chips and chips treated with 10 nM nin-
tedanib were perfused with 70 kDa RITC-dextran, and the 
Angiogenesis 
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Fig. 1  Microfluidic chip specifications and establishment of in  vitro 
perfusable microvasculature network. a Microfluidic chip fabricated 
by PDMS soft lithography and bonded to coverslip, filled with red sil-
icon dye for better visualization of the compartments. b Layout of the 
chip: NL-FBs in fibrin gel in the two outermost chambers (green), co-
culture of HUVECs and NL-FBs in fibrin gel in the circular central 
chamber (blue), and cell culture media (red) in two symmetric micro-
channels. Close-up view shows the pillars of different compartments, 
indicated by yellow arrows. Scale bar: 2 mm. c Representative image 
showing the formation of the interendothelial junctions through the 
expression of PECAM-1 between adjacent HUVECs. Blue: DAPI, 
green: PECAM-1. Scale bar: 100 µm. d Representative image of the 
microvasculature network immunostained for endothelial cell marker 
PECAM-1 (green). This image from the central chamber was taken 
after 7 days of co-culturing. Scale bar: 200 µm
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Fig. 2  Cells maintain proliferation and viability when treated with nint-
edanib. a Proliferation rate of HUVECs, NL-FBs, and co-culture. Cells 
were imaged and counted after live/dead staining, and the proliferation 
rate was determined by calculating the ratio of live cells on each day 
to the number of cells originally seeded on day 0. Each condition was 
assessed in duplicate, with at least four sample images used for count-
ing. b Viability of HUVECs, NL-FBs, and co-culture. The assay was 
performed in three independent experiments with duplicate wells
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fluorescent dye filled the microvasculature structures in 
the central chamber. In the presence of 10 nM nintedanib, 
dye leaked into the interstitial space, whereas no leakage 
from the microvasculature wall was observed in untreated 
networks (Fig. 3a). The calculated permeability coeffi-
cients were (1.5 ± 0.32) × 10−6 cm/s for untreated chips and 
(1.04 ± 0.36) × 10−3 cm/s for chips treated with 10 nM nint-
edanib. Thus, nintedanib treatment significantly (p < 0.0056) 
increased microvascular permeability (Fig. 3b). Permeability 
coefficients were calculated for untreated and 10 nM nin-
tedanib-treated chips because, at higher concentrations of 
nintedanib, formation of perfusable microvasculature archi-
tecture was inhibited. In the untreated and 10 nM nintedanib 
settings, microvasculatures were more streamlined and open 
to the side microchannels through adjusted trapezoidal open-
ings, whereas networks treated with 30 and 100 nM nin-
tedanib had more tortuous microvessels that were largely 
closed to the access pillars (Supplementary Material Fig. 
S1).
Nintedanib decreases microvasculature density
The PECAM-1 protein, encoded by the PECAM1 gene, 
makes up a large portion of endothelial cell intercellular 
junctions and is widely recognized as an endothelial cell 
marker [24]. To quantify the effects of nintedanib treatment 
on microvasculature networks, we defined PECAM-1-pos-
itive regions in the central chamber as vascularized areas 
and analyzed the amount of vascularized area as well as 
network features and morphology. Representative images 
show that, in addition to reducing vessel density, nintedanib 
treatment altered microvessel morphology (Fig. 4a). For 
clearer visualization of these differences, we performed 
axial thinning of the networks using the DiameterJ 1-018 
plugin in Fiji. Nintedanib treatment clearly decreased the 
quantity of vascular intersections and sprouting (Fig. 4a). 
Increasing concentrations of nintedanib led to a decrease in 
the total amount of vascularized area in the central chamber, 
indicating that nintedanib reduces microvasculature density 
in vitro (Fig. 4a). In untreated chips, approximately 58% of 
the central chamber was covered by the microvasculature 
network, whereas 100 nM nintedanib treatment reduced 
microvasculature coverage to approximately 13% (Fig. 4b).
Nintedanib shrinks microvessel diameter
To assess the effect of nintedanib on microvasculature archi-
tecture, we examined the diameters of individual microves-
sels and obtained the diameter distribution of the network. 
Nintedanib had a thinning effect on microvessel diameter 
(Fig. 5, Fig. S3). In addition to shrinking vessel diameter, 
nintedanib dramatically decreased the number of vessels in 
the central chamber (Fig. S2).
Nintedanib inhibits fibroblast organization 
around endothelial vessels
To examine the effect of nintedanib on endothelial–fibroblast 
interactions, we used membrane labeling to track live cells. 
We observed that nintedanib treatment affected the asso-
ciation of fibroblasts with endothelial vessels. In untreated 
chips, NL-FBs spread around microvascular segments and 
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Fig. 3  Nintedanib affected microvascular barrier integrity and per-
meability. a 70  kDa RITC-dextran was added to one of the reser-
voirs and filled the microvasculature in the central chamber. Images 
represent a segment of the central chamber and are overlays of the 
red channel and bright field. Time interval between the two images 
in each case is 1  min. In the 10  nM-treated chip, fluorescent dye 
leaked from the vasculature into the fibrin gel. The robust integrity 
of untreated microvessel walls kept the dye inside the vasculature and 
prevented any obvious leakage into the fibrin gel. Scale bar: 150 µm. 
b Time lapse images were recorded, and the vascular permeability 
coefficient was calculated from measurements of the fluorescence 
intensity across vascular walls over time. At least five areas per chip 
were analyzed. Treatment started on day 1. n = 6 and p < 0.0056
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a b
Fig. 4  Nintedanib reduces density of in  vitro microvessel architec-
ture. a Top row: representative images of vascular morphologies 
of untreated chips and nintedanib-treated chips. Cells were immu-
nostained for PECAM-1 (green). Images are projections of z-stacks 
acquired by confocal microscopy. Scale bar: 150  µm. Bottom row: 
axial thinning of microvasculature networks for better visualization 
of vascular intersections. Nintedanib decreases the number of vas-
cular intersections and the amount of vascular sprouting. b Vascu-
larized area was defined as the ratio of PECAM-1-positive areas to 
the whole area of the central chamber. Calculated vascularized areas 
were as follows: 58.13 ± 1.45% (untreated chip), 29.4 ± 2.71% (10 nM 
nintedanib), 24.67 ± 1.2% (30  nM nintedanib), and 13.1 ± 0.8% 
(100  nM nintedanib). Three regions were examined for each condi-
tion p < 0.0007
Fig. 5  Diameter distribution of microvasculature network. Frequency 
of individual diameters in the vasculature network in untreated  (0 
nM) and nintedanib-treated chips  (10 nM and 100  nM). Segmented 
microscopy images were analyzed by the DiameterJ 1-018 plugin. 
Nintedanib reduced the diameter of vessels and the frequency of ves-
sels larger than 25 µm. n = 3 per condition. Treatment with nintedanib 
started on day 1
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Fig. 6  Fibroblasts organization in the microvessels. a Live cells were 
imaged, and segments of the central chambers on day 7 are shown. 
HUVECs are shown in green, and NL-FBs are shown in red. In 
untreated chips, NL-FBs appeared to wrap around the endothelial 
vessels, whereas treatment with 50 nM nintedanib caused NL-FBs to 
localize away from endothelial lumens. Nintedanib treatment started 
on day 1. Scale bar: 200  µm. b Colocalized areas were defined as 
regions where fibroblasts overlapped endothelial cells. Nintedanib 
decreased fibroblast coverage around endothelial cells and signifi-
cantly decreased the amount of colocalized area
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aligned with the microvessel, and NL-FBs clearly influenced 
vessel orientation. At the end of day 7, untreated vascula-
tures had developed into streamlined endothelial vessels 
externally wrapped by fibroblasts (Fig. 6a). Treatment with 
50 nM nintedanib inhibited the alignment of NL-FBs around 
endothelial microvessels; NL-FBs located in the vicinity 
of vessels did not spread around the vessels. After 7 days 
of 50 nM treatment, microvasculatures were tortuous and 
lacked an exterior sheath of fibroblasts (Fig. 6a). Quantifica-
tion of the colocalization of HUVECs and NL-FBs revealed 
that nintedanib significantly inhibited fibroblast organization 
around endothelial vessels (Fig. 6b).
Nintedanib prevents fibroblast invasion
To achieve a clear understanding of nintedanib influence on 
fibroblast migration, we wished to observe the movement 
of fibroblasts from the side chambers toward the endothelial 
cells in the central chamber. Cells were seeded separately: 
green-labeled HUVECs in the central chamber and red-
labeled NL-FBs in the side chambers. In untreated condi-
tions, fibroblasts migrated within the flow microchannels 
toward the endothelial cells and invaded the central chamber 
by migration through the fibrin gel. After treatment with 
50 nM nintedanib, NL-FBs reached the perimeter of the 
central chamber via the microchannels, but remained in the 
entrances and did not move into the central chamber (Fig. 7, 
Fig. S4). Additionally, 50 nM nintedanib treatment caused 
fewer fibroblasts to localize near the central chamber (data 
not shown). In untreated chips, fibroblast invasion of the 
central chamber occurred through a majority of the open-
ings, whereas in 50 nM nintedanib-treated chips, fibroblasts 
did not migrate through any of the openings.
Nintedanib breaks vessel–vessel connection 
in pre‑existing microvasculature network
To address the effect of nintedanib on remodeling of a pre-
formed microvasculature network, we modified our treat-
ment protocol such that cells were seeded on chips as for 
other experiments, but 50 nM nintedanib treatment started 
on day 4, after the premature vasculature network formed, 
rather than on day 1. Sprouting, vascular formation, and 
lumen formation of endothelial cell clusters with neighbor-
ing cells took place from day 1 to day 4 (Fig. 8). After addi-
tion of 50 nM nintedanib on day 4, existing vessel–vessel 
connections gradually weakened and finally disappeared 
(Fig. 8). In addition to its anti-vasculogenic effect, nint-
edanib remodeled the pre-existing microvasculature network 
by shrinking intervascular connections and inhibiting vascu-
lar sprouting (Supplementary Material Video S2).
Discussion
Advanced in vitro microfluidic models enable visualization 
of biological dynamics, elimination of the interspecies varia-
tions, and reduction of the amount of cells and reagents to be 
used. In addition, these models offer a controllable investiga-
tion of vascularization to develop on-chip models that can be 
used in the future for optimization and development of drug 
treatments on personalized vasculature networks [25]. In this 
study, for the first time, fibroblasts acquired from healthy 
lung tissue of patients were utilized to establish a 3D, sta-
ble and perfusable microvasculature network in vitro. After 
establishment of this network, we investigated the effects 
of the triple tyrosine kinase inhibitor nintedanib on in vitro 
Fig. 7  Fibroblasts microvasculature invasion. Representative overlay 
images of central chambers on day 7. Trapezoidal structures indicate 
the pillars around the central chamber. White arrows show the loca-
tion of the fibroblasts. In untreated chips, NL-FBs (red) migrated 
across the microchannel and through the entrances to the central 
chamber filled with HUVECs (green), but treatment with 50 nM nin-
tedanib inhibited migration and invasion through the fibrin gel. Scale 
bars: 200 µm
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human microvasculature system. We demonstrated the 
impact of nintedanib on vascular permeability, vessel den-
sity, vascular morphology, endothelial–fibroblast interaction, 
and fibroblast invasion in vitro. Using our microvasculature-
on-chip model, we showed that treatment with nintedanib 
significantly increased vascular permeability, decreased ves-
sel density by both reducing number of vessels and shrink-
ing the vessels themselves, inhibited fibroblast recruitment 
to endothelial vasculatures, constrained fibroblast invasion 
toward the vasculature region, and weakened vessel–vessel 
connections of existing microvasculatures.
Before testing nintedanib in our model, we assessed its 
cytotoxicity on monoculture and co-culture of HUVECs 
and NL-FBs in concentrations up to 100 nM. Alamar blue 
and live-dead staining assays revealed that all cell cultures 
maintain their viability and proliferation when exposed to 
up to 100 nM treatment with nintedanib. This result stands 
in contrast to a previous report, where treatment of either 
VEGF- or bFGF-stimulated HUVECs with nintedanib 
resulted in inhibition of cell proliferation and apoptosis with 
EC50 values of less than 10 and 290 nM, respectively [6]. 
However, in the present study, HUVECs were stimulated 
with both VEGF and FGF (which were present in the fully 
supplemented EGM-2 media), so they were expected to be 
more durable against the toxic effect of nintedanib. Previous 
studies showed no evidence of acute toxicity on human lung 
fibroblasts at nintedanib concentrations up to 1 µM [26]. It 
has also been shown that nintedanib inhibits proliferation of 
lung fibroblasts significantly only at concentrations greater 
than 500 nM [26].
Interestingly, although nintedanib did not have adverse 
effect on cellular viability and proliferation, when adminis-
tered on-chip during microvessel formation, it affected the 
in vitro microvasculature at concentrations as low as 10 nM. 
For direct comparison, the concentrations we selected for 
nintedanib to be administered on-chip is approximately 
between 0.7 and 1.4 times of its concentration in human 
plasma [27].
Furthermore, nintedanib-treated in vitro vessels showed 
a significant increase in vascular leakage across the ves-
sel wall. On-chip administration of nintedanib increased 
the permeability of in vitro microvessels by three orders 
of magnitude. Nintedanib also prevented fibroblasts from 
elongating and ensheathing endothelial vessel segments, 
possibly by interfering with paracrine PDGF signaling 
between endothelial cells and fibroblasts. PDGF is respon-
sible for the chemoattraction and proliferation of pericytes 
and fibroblasts in the vessel walls [5]. In IPF, in addition to 
fibroblasts, PDGF is found in endothelial cells and epithe-
lial cells which suggests contribution of PDGF in vascular 
remodeling [28]. Inhibiting PDGF/PDGFR signaling cas-
cade interferes chemoattraction and migration of fibroblasts 
and results in formation of unstable network of the microvas-
culatures. The presence of fibroblasts is known to directly 
affect the permeability and morphology of microvasculature 
in vitro; perivascular cells wrap around vessels, stabilize the 
Fig. 8  Remodeling of pre-existing microvasculature network. Images 
represent vascular remodeling in three different segments of the cen-
tral chamber on days 1–7. Nintedanib treatment (50 nM) started on 
day 4. HUVECs are shown in green. Red arrows indicate the regions 
where vessel–vessel connections progressively disappeared. Scale 
bar: 60 µm
 Angiogenesis
1 3
intercellular junctions, increase basement membrane deposi-
tion, and thus decrease the permeability of the microvascu-
latures [12, 13, 29–31]. Therefore, the high leakage could 
be explained by lack of perivascular coverage and junctional 
stability via PDGF signaling.
Ackermann et al. reported that nintedanib increased the 
intervessel distance in vivo by a factor of 1.7 and decreased 
vessel diameter from 5.1 ± 1.38 to 3.71 ± 1.0 µm, indicating 
a significant reduction in vessel density [10]. These results 
are consistent with our data showing that treatment with 
nintedanib considerably decreases the vascular density and 
diameter in vitro. In addition to modulating several signaling 
pathways and controlling endothelial cells during angiogen-
esis, VEGF is the master regulator of vessel formation and 
sprouting [32]. Although the precise mechanism of VEGF 
in angiogenesis is not fully elucidated, variety of biologic 
responses have been reported for VEGF–VEGFR binding: 
inhibiting endothelial cells apoptosis, regulating migration 
and proliferation of these cells, increasing vascular perme-
ability and maintaining vascular integrity [11, 33–36]. To 
regulate sprouting, the spatial distribution of VEGF loosens 
cell–cell adherence, directs tip cell migration and determines 
stalk cells proliferation [37]. Inhibition of VEGF/VEGFR 
signaling could have harmful effect on vascular integrity 
by promoting endothelial cells apoptosis [11]. Addition-
ally, VEGF blocking down regulates vascular sprouting and 
decreases capillary branching [28]. Interestingly, blockade 
of VEGF with specific antibodies was shown to decrease 
the number of capillary-like tubes by up to 70%, further cor-
roborating our finding [31]. FGF is heparin binding growth 
factor that induces endothelial cells proliferation and migra-
tion [38]. FGF is also mediator of preliminary step in angio-
genesis by contributing in ECM degradation through plas-
minogen activator expression [39]. Inhibition of FGF/FGFR 
signaling could constrain endothelial cells migration, cause 
prevention of ECM degradation and show similar effect on 
sprouting as VEGF/VEGFR blocking.
The invasion of human lung fibroblasts was recently stud-
ied using the Matrigel invasion assay [26]. The presence of 
nintedanib in the cell culture medium reduced the invasion 
capability of lung fibroblasts [26]. The specific design of 
our microvasculature platform enabled examination of the 
invasion of NL-FBs from fibrin gel into EGM2 and also 
into fibrin gel with incorporated HUVECs. The low density 
of lung fibroblasts at the entrances of the central chamber 
suggests that NL-FBs are constrained from invading into 
a medium in the presence of nintedanib. Several in vivo 
studies about the effect of nintedanib on vascular density 
in lung cancer and fibrosis models revealed that nintedanib 
acts on pre-existing microvessel networks [10, 40]. Simi-
larly, we found that in addition to inhibiting vasculogenesis, 
nintedanib remodels pre-existing microvessels by shrinking 
and rupturing intravascular connections.
We sought to explore the anti-angiogenic and anti-vascu-
logenic effects of nintedanib with the goal of evaluating its 
use in treatment of IPF, but our approach has two caveats. 
We utilized HUVECs in our in vitro microvasculature model, 
but HUVECs differ from lung vascular endothelial cells in 
terms of gene expression and morphology [10, 41]. We also 
utilized normal lung fibroblasts, which have different lev-
els of PDGFR and FGFR expression than IPF fibroblasts 
[7]. Ideally, the microvasculature architecture in the in vitro 
model would mimic IPF pathology, which may be possible if 
fibroblasts from IPF patients were seeded into the chip with 
endothelial cells. Such an in vitro diseased microvasculature 
model would be very useful for drug discovery and testing.
Advanced in vitro microvasculature models open new 
prospects to study the mode of action of treatment agents 
such as nintedanib. These experimental platforms can address 
fundamental questions of drug effects on angiogenesis and 
vasculogenesis and can be used for developing and optimiz-
ing drug treatments in personalized vasculature models in 
the future. In summary, our work revealed that nintedanib 
treatment at clinically relevant concentrations did not affect 
cell viability but did significantly affect neovasculogenesis 
by loosening vascular barrier integrity, increasing perme-
ability, shrinking microvessels, decreasing vascular density, 
and preventing fibroblast organization around endothelial 
vasculatures. The effect of nintedanib on microvasculature 
architecture has previously been studied in vivo [10], and 
our in vitro 3D model of human microvasculature represents 
an exciting approach because it permits to study of the effect 
of nintedanib on isolated human microvessels and resolve 
cell–cell interactions in greater detail than in vivo studies.
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